Answers are grounded in this paper and cite their sources.
The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.
No takes yet. Share an insight, caveat, or question.
Rowin et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: